Minnelide effectively eliminates CD133+ side population in pancreatic cancer

Alice Nomura, Olivia McGinn, Vikas Dudeja, Veena Sangwan, Ashok Saluja, Sulagna Banerjee

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Background: Pancreatic Ductal Adenocarcinoma (PDAC) is a devastating disease hallmarked by limited patient survival. Resistance to chemotherapy, a major cause of treatment failure in PDAC patients, is often attributed to Cancer Stem Cells (CSCs). Pancreatic CSCs are a small subset of quiescent cells within a tumor represented by surface markers like CD133. These cells are responsible not only for tumor recurrence, but also poor prognosis based on their "stem-like" characteristics. At present, conventional therapy is directed towards rapidly dividing PDAC cells and thus fails to target the CSC population. Methods: MIA PaCa-2, S2-013 and AsPC-1 were treated with 12.5 nM triptolide (12T cells) for 7days. The surviving cells were recovered briefly in drug-free growth media and then transferred to Cancer Stem cell Media (CSM). As a control, untreated cells were also transferred to CSM media (CSM). The 12T and CSM cells were tested for stemness properties using RNA and protein markers. Low numbers of CSM and 12T cells were implanted subcutaneously in athymic nude mice to study their tumorigenic potential. 12T and CSM cells were sorted for CD133 expression and assayed for their colony forming ability and sphere forming ability. Invasiveness of 12T cells, CSM and MIA PaCa-2 were compared using Boyden chamber assays. Results: Treated 12T cells displayed increased expression of the surface marker CD133 and the drug transporter ABCG2 compared to untreated cells (CSM cells). Both 12T and CSM cells formed subcutaneous tumors in mice confirming their tumor-initiating properties. When tested for invasion, 12T cells had increased invasiveness compared to CSM cells. CD133+ cells in both CSM and 12T showed greater colony and sphere forming ability compared to CD133- cells from each group. Consistent with these data, when injected subcutaneously in mice, CD133- cells from CSM or 12T did not form any tumors whereas CD133+ cells from both groups showed tumor formation at a very low cell number. Despite pre-exposure to triptolide in 12T CD133+ cells, treatment of tumors formed by these cells with Minnelide, a triptolide pro-drug, showed significant tumor regression. Conclusion: Our results indicated that triptolide enhanced and enriched the "stemness" in the PDAC cell lines at a low dose of 12.5 nM, but also resulted in the regression of tumors derived from these cells.

Original languageEnglish (US)
Article number200
JournalMolecular Cancer
Volume14
Issue number1
DOIs
StatePublished - Nov 23 2015
Externally publishedYes

Fingerprint

Pancreatic Neoplasms
Neoplastic Stem Cells
Population
Neoplasms
14-O-phosphonooxymethyltriptolide
Adenocarcinoma
Nude Mice

ASJC Scopus subject areas

  • Molecular Medicine
  • Oncology
  • Cancer Research

Cite this

Minnelide effectively eliminates CD133+ side population in pancreatic cancer. / Nomura, Alice; McGinn, Olivia; Dudeja, Vikas; Sangwan, Veena; Saluja, Ashok; Banerjee, Sulagna.

In: Molecular Cancer, Vol. 14, No. 1, 200, 23.11.2015.

Research output: Contribution to journalArticle

@article{ec49de07dbbc4cffa622741d0555a938,
title = "Minnelide effectively eliminates CD133+ side population in pancreatic cancer",
abstract = "Background: Pancreatic Ductal Adenocarcinoma (PDAC) is a devastating disease hallmarked by limited patient survival. Resistance to chemotherapy, a major cause of treatment failure in PDAC patients, is often attributed to Cancer Stem Cells (CSCs). Pancreatic CSCs are a small subset of quiescent cells within a tumor represented by surface markers like CD133. These cells are responsible not only for tumor recurrence, but also poor prognosis based on their {"}stem-like{"} characteristics. At present, conventional therapy is directed towards rapidly dividing PDAC cells and thus fails to target the CSC population. Methods: MIA PaCa-2, S2-013 and AsPC-1 were treated with 12.5 nM triptolide (12T cells) for 7days. The surviving cells were recovered briefly in drug-free growth media and then transferred to Cancer Stem cell Media (CSM). As a control, untreated cells were also transferred to CSM media (CSM). The 12T and CSM cells were tested for stemness properties using RNA and protein markers. Low numbers of CSM and 12T cells were implanted subcutaneously in athymic nude mice to study their tumorigenic potential. 12T and CSM cells were sorted for CD133 expression and assayed for their colony forming ability and sphere forming ability. Invasiveness of 12T cells, CSM and MIA PaCa-2 were compared using Boyden chamber assays. Results: Treated 12T cells displayed increased expression of the surface marker CD133 and the drug transporter ABCG2 compared to untreated cells (CSM cells). Both 12T and CSM cells formed subcutaneous tumors in mice confirming their tumor-initiating properties. When tested for invasion, 12T cells had increased invasiveness compared to CSM cells. CD133+ cells in both CSM and 12T showed greater colony and sphere forming ability compared to CD133- cells from each group. Consistent with these data, when injected subcutaneously in mice, CD133- cells from CSM or 12T did not form any tumors whereas CD133+ cells from both groups showed tumor formation at a very low cell number. Despite pre-exposure to triptolide in 12T CD133+ cells, treatment of tumors formed by these cells with Minnelide, a triptolide pro-drug, showed significant tumor regression. Conclusion: Our results indicated that triptolide enhanced and enriched the {"}stemness{"} in the PDAC cell lines at a low dose of 12.5 nM, but also resulted in the regression of tumors derived from these cells.",
author = "Alice Nomura and Olivia McGinn and Vikas Dudeja and Veena Sangwan and Ashok Saluja and Sulagna Banerjee",
year = "2015",
month = "11",
day = "23",
doi = "10.1186/s12943-015-0470-6",
language = "English (US)",
volume = "14",
journal = "Molecular Cancer",
issn = "1476-4598",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Minnelide effectively eliminates CD133+ side population in pancreatic cancer

AU - Nomura, Alice

AU - McGinn, Olivia

AU - Dudeja, Vikas

AU - Sangwan, Veena

AU - Saluja, Ashok

AU - Banerjee, Sulagna

PY - 2015/11/23

Y1 - 2015/11/23

N2 - Background: Pancreatic Ductal Adenocarcinoma (PDAC) is a devastating disease hallmarked by limited patient survival. Resistance to chemotherapy, a major cause of treatment failure in PDAC patients, is often attributed to Cancer Stem Cells (CSCs). Pancreatic CSCs are a small subset of quiescent cells within a tumor represented by surface markers like CD133. These cells are responsible not only for tumor recurrence, but also poor prognosis based on their "stem-like" characteristics. At present, conventional therapy is directed towards rapidly dividing PDAC cells and thus fails to target the CSC population. Methods: MIA PaCa-2, S2-013 and AsPC-1 were treated with 12.5 nM triptolide (12T cells) for 7days. The surviving cells were recovered briefly in drug-free growth media and then transferred to Cancer Stem cell Media (CSM). As a control, untreated cells were also transferred to CSM media (CSM). The 12T and CSM cells were tested for stemness properties using RNA and protein markers. Low numbers of CSM and 12T cells were implanted subcutaneously in athymic nude mice to study their tumorigenic potential. 12T and CSM cells were sorted for CD133 expression and assayed for their colony forming ability and sphere forming ability. Invasiveness of 12T cells, CSM and MIA PaCa-2 were compared using Boyden chamber assays. Results: Treated 12T cells displayed increased expression of the surface marker CD133 and the drug transporter ABCG2 compared to untreated cells (CSM cells). Both 12T and CSM cells formed subcutaneous tumors in mice confirming their tumor-initiating properties. When tested for invasion, 12T cells had increased invasiveness compared to CSM cells. CD133+ cells in both CSM and 12T showed greater colony and sphere forming ability compared to CD133- cells from each group. Consistent with these data, when injected subcutaneously in mice, CD133- cells from CSM or 12T did not form any tumors whereas CD133+ cells from both groups showed tumor formation at a very low cell number. Despite pre-exposure to triptolide in 12T CD133+ cells, treatment of tumors formed by these cells with Minnelide, a triptolide pro-drug, showed significant tumor regression. Conclusion: Our results indicated that triptolide enhanced and enriched the "stemness" in the PDAC cell lines at a low dose of 12.5 nM, but also resulted in the regression of tumors derived from these cells.

AB - Background: Pancreatic Ductal Adenocarcinoma (PDAC) is a devastating disease hallmarked by limited patient survival. Resistance to chemotherapy, a major cause of treatment failure in PDAC patients, is often attributed to Cancer Stem Cells (CSCs). Pancreatic CSCs are a small subset of quiescent cells within a tumor represented by surface markers like CD133. These cells are responsible not only for tumor recurrence, but also poor prognosis based on their "stem-like" characteristics. At present, conventional therapy is directed towards rapidly dividing PDAC cells and thus fails to target the CSC population. Methods: MIA PaCa-2, S2-013 and AsPC-1 were treated with 12.5 nM triptolide (12T cells) for 7days. The surviving cells were recovered briefly in drug-free growth media and then transferred to Cancer Stem cell Media (CSM). As a control, untreated cells were also transferred to CSM media (CSM). The 12T and CSM cells were tested for stemness properties using RNA and protein markers. Low numbers of CSM and 12T cells were implanted subcutaneously in athymic nude mice to study their tumorigenic potential. 12T and CSM cells were sorted for CD133 expression and assayed for their colony forming ability and sphere forming ability. Invasiveness of 12T cells, CSM and MIA PaCa-2 were compared using Boyden chamber assays. Results: Treated 12T cells displayed increased expression of the surface marker CD133 and the drug transporter ABCG2 compared to untreated cells (CSM cells). Both 12T and CSM cells formed subcutaneous tumors in mice confirming their tumor-initiating properties. When tested for invasion, 12T cells had increased invasiveness compared to CSM cells. CD133+ cells in both CSM and 12T showed greater colony and sphere forming ability compared to CD133- cells from each group. Consistent with these data, when injected subcutaneously in mice, CD133- cells from CSM or 12T did not form any tumors whereas CD133+ cells from both groups showed tumor formation at a very low cell number. Despite pre-exposure to triptolide in 12T CD133+ cells, treatment of tumors formed by these cells with Minnelide, a triptolide pro-drug, showed significant tumor regression. Conclusion: Our results indicated that triptolide enhanced and enriched the "stemness" in the PDAC cell lines at a low dose of 12.5 nM, but also resulted in the regression of tumors derived from these cells.

UR - http://www.scopus.com/inward/record.url?scp=84947712555&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947712555&partnerID=8YFLogxK

U2 - 10.1186/s12943-015-0470-6

DO - 10.1186/s12943-015-0470-6

M3 - Article

VL - 14

JO - Molecular Cancer

JF - Molecular Cancer

SN - 1476-4598

IS - 1

M1 - 200

ER -